A phase II study of oral VP-16-213 in non-seminomatous testicular cancer

Publisher Website

1 February 1981

journal article
research article
Published by Elsevier in European Journal of Cancer (1965)

Vol. 17 (2), 245-249
https://doi.org/10.1016/0014-2964(81)90043-8

Abstract

No abstract available

This publication has 9 references indexed in Scilit:

VP16-213 as a single agent in advanced testicular tumors
European Journal of Cancer (1965), 1980
Etoposide (VP-16-213)
Cancer Treatment Reviews, 1979
VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES
1978
EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN TREATMENT OF SOLID TUMOURS
The Lancet, 1977
EPIPODOPHYLLIN DERIVATIVE (VP 16-213) IN MALIGNANT TERATOMAS AND CHORIOCARCINOMAS
The Lancet, 1977
VM 26 and VP 16–213: A comparative analysis
Cancer, 1977
COMPARISON OF BIOLOGIC ACTIVITY OF VP-16-213 GIVEN IV AND ORALLY IN CAPSULES OR DRINK AMPULES
1976
Activity of a new glycosidic lignan derivative (VP 16-213) related to podophyllotoxin in experimental tumors
European Journal of Cancer (1965), 1973

Cited by 35 articles